Adicet Bio (ACET) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed Adicet Bio (ACET) over the past year, losing 4.5% versus a loss of 61.6%. Over five years, INMB leads with a -89.8% price change compared with -95.6% for ACET. Adicet Bio is the larger company by market cap ($52.5 million vs $52.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | INMB |
|---|---|---|
| Share price | $5.61 | $1.89 |
| Market cap | $52.52M | $52.45M |
| 1-day change | -2.26% | +3.28% |
| YTD return | -33.37% | +21.15% |
| 1-year return | -61.64% | -4.55% |
| 5-year return | -95.64% | -89.85% |
| EPS (TTM) | $-10.24 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $2.60 |
| 52-week low | $5.55 | $1.09 |
| Distance from 52-week high | -67.83% | -27.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +520.86% | +270.37% |
| Average volume | 172.38K | 402.12K |
| Shares outstanding | 9.36M | 27.75M |
| Employees | 102 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed ACET by 57.1 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
ACET vs INMB FAQ
Which is bigger, Adicet Bio or INmune Bio?
Adicet Bio (ACET) is larger, with a market capitalization of $52.52M compared with $52.45M for INmune Bio (INMB).
Which stock has performed better over the past year, ACET or INMB?
INMB returned -4.55% over the past 12 months, compared with -61.64% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and INmune Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Adicet Bio and Biotechnology: Biological Products (No Diagnostic Substances) for INmune Bio.